Skip to main content

Table 1 Patient characteristics and clinical outcomes according to the two cohorts

From: High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study

N. Pts Age (years) Sex ECOG PS Primary site DFI (months) Basal LDH N. cycle of chemotherapy Disease sites Response (duration) Survival (months)
Cohort A
1 69 F 1 Skin 4 360 7 Lung Soft tissue Lymph nodes PR (9 months) 19+
2 76 M 1 Skin 2 238 6 Soft tissue PR (7 months) 17+
3 49 M 1 Unknown _ 324 2 Lung Bowel PR (6 months) CR (2 months) 14
4 73 M 2 Skin 96 379 1 Lung Brain SD (4 months) 4
5 62 F 1 Anal mucosa 11 403 7 Endopelvic mass Lymph nodes PD 9
6 71 M 1 Skin 36 291 6 Soft tissue Lymph nodes Bone SD (5 months) 14
7 64 M 1 Scalp 7 251 2 Lung Bone PD 13+
Cohort B
1 64 M 1 Skin 10 474 3 Liver Lymph nodes Spleen Lung PD 5
2 38 F 2 Skin 11 309 7 Soft tissue Adrenal gland Bone PR (6 months) 10
3 76 F 1 Skin 25 289 7 Soft tissue Lymph nodes SD (5 months) 12
4 48 F 1 Skin 24 394 6 Lung SD (7 months) 14+
5 42 M 0 Skin 12 442 3 Liver Lung PD 13+
6 75 F 1 Skin 12 839 8 Soft tissue Lymph nodes Liver RP (11+ months) 13+
7 59 M 0 Skin 24 330 6 Lung Lymph nodes SD (4 months) 13+
  1. Abbreviations: LDH: lactate dehydrogenase; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.